Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes

BMC Neurology

Volumn 7, Issue , 2007, Pages

  Ergul, Adviye ^a,b   Elgebaly, Mostafa M ^a   Middlemore, Mary Louise ^a   Li, Weiguo ^a   Elewa, Hazem ^a   Switzer, Jeffrey A ^b   Hall, Christiana ^b   Kozak, Anna ^a,c   Fagan, Susan C ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Specialty Care Service Line Veterans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; GOTO KAKIZAKI RAT; HEMATOMA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; REPERFUSION INJURY; RISK ASSESSMENT; ANIMAL; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBRAL ARTERY DISEASE; DISEASE MODEL; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; METABOLISM; METHODOLOGY; NEUROLOGIC EXAMINATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION; WISTAR RAT;

GELATINASE A;

ANIMALS; BLOOD GLUCOSE; BRAIN INFARCTION; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASE 2; NEUROLOGIC EXAMINATION; RATS; RATS, WISTAR; REPERFUSION; SEVERITY OF ILLNESS INDEX;

EID: 36649002215     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-7-33     Document Type: Article

References (30)

1. Kernan WN Inzucchi SE: Type 2 diabetes mellitus and insulin resistance: Stroke prevention and management. Curr Treat Options Neurol 2004, 6(6):443-450. 10.1007/s11940-004-0002-y 15461922
2. Kaarisalo MM Raiha I Sivenius J Immonen-Raiha P Lehtonen A Sarti C Mahonen M Torppa J Tuomilehto J Salomaa V: Diabetes worsens the outcome of acute ischemic stroke Diabetes Res. Clin Pract 2005, 69(3):293-298. 10.1016/j.diabres.2005.02.001 16098927
3. Weimar C Mieck T Buchthal J Ehrenfeld CE Schmid E Diener HC: Neurologic worsening during the acute phase of ischemic stroke. Arch Neurol 2005, 62(3):393-397. 10.1001/archneur.62.3.393 15767504
4. Baird TA Parsons MW Phanh T Butcher KS Desmond PM Tress BM Colman PG Chambers BR Davis SM: Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003, 34(9):2208-2214. 10.1161/ 01.STR.0000085087.41330.FF 12893952
5. Cipolla MJ McCall AL Lessov N Porter JM: Reperfusion decreases myogenic reactivity and alters middle cerebral artery function after focal cerebral ischemia in rats. Stroke 1997, 28(1):176-180. 8996508
6. de Courten-Myers GM Kleinholz M Holm P DeVoe G Schmitt G Wagner KR Myers RE: Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med 1992, 21(2):120-126. 10.1016/S0196-0644(05)80144-1 1739195
7. Kawai N Keep RF Betz AL: Hyperglycemia and the vascular effects of cerebral ischemia. Stroke 1997, 28(1):149-154. 8996504
8. Venables GS Miller SA Gibson G Hardy JA Strong AJ: The effects of hyperglycaemia on changes during reperfusion following focal cerebral ischaemia in the cat. J Neurol Neurosurg Psychiatry 1985, 48(7):663-669. 4031911
9. Harris AK Hutchinson JR Sachidanandam K Johnson MH Dorrance AM Stepp DW Fagan SC Ergul A: Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: Role of endothelin-1. Diabetes 2005, 54(9):2638-2644. 10.2337/diabetes.54.9.2638 16123352
10. Lindsberg PJ Roine RO: Hyperglycemia in acute stroke. Stroke 2004, 35(2):363-364. 10.1161/01.STR.0000115297.92132.84 14757880
11. Fagan SC Garcia JH: Hemorrhagic transformation in focal cerebral ischemia: Influence of time to artery reopening and tissue plasminogen activator. Pharmacotherapy 1999, 19(2):139 -142. 10.1592/ phco.19.3.139.30932 10030763
12. Harris AK Ergul A Kozak A Machado LS Johnson MH Fagan SC: Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci 2005, 6:49. 1190186 16078993 10.1186/1471-2202-6-49
13. Fagan SC Kozak A Hill WD Pollock DM Xu L Johnson MH Ergul A Hess DC: Hypertension after experimental cerebral ischemia: Candesartan provides neurovascular protection. J Hypertens 2006, 24(3):535-539. 10.1097/ 01.hjh.0000209990.41304.43 16467657
14. Maeda K Hata R Hossmann KA: Regional metabolic disturbances and cerebrovascular anatomy after permanent middle cerebral artery occlusion in C57black/6 and SV129 mice. Neurobiol Dis 1999, 6(2):101-108. 10.1006/ nbdi.1998.0235 10343325
15. Portik-Dobos V Harris AK Song W Hutchinson J Johnson MH Imig JD Pollock DM Ergul A: Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol 2005. 16239374
16. Bruno A Levine SR Frankel MR Brott TG Lin Y Tilley BC Lyden PD Broderick JP Kwiatkowski TG Fineberg SE: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002, 59(5):669-674. 12221155
17. Bruno A Biller J Adams HP Jr Clarke WR Woolson RF Williams LS Hansen MD: Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology 1999, 52(2):280-284. 9932944
18. Martini SR Kent TA: Hyperglycemia An acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2006. 16804552
19. Capes SE Hunt D Malmberg K Pathak P Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke 2001, 32(10):2426-2432. 10.1161/ hs1001.096194 11588337
20. Monteiro P Goncalves L Providencia LA: Diabetes and cardiovascular disease: The road to cardioprotection. Heart 2005, 91(12):1621-1625. 10.1136/hrt.2005.063008 16287756
21. Huang PL: Nitric oxide and cerebral ischemic preconditioning. Cell Calcium 2004, 36(3-4):323-329. 10.1016/j.ceca.2004.02.007 15261488
22. Schaller B Graf R: Cerebral ischemic preconditioning. An experimental phenomenon or a clinical important entity of stroke prevention?. J Neurol 2002, 249(11):1503-1511. 10.1007/s00415-002-0933-8 12420088
23. del Zoppo GJ Mabuchi T: Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 2003, 23(8):879-894. 10.1097/ 01.WCB.0000078322.96027.78 12902832
24. del Zoppo GJ von Kummer R Hamann GF: Ischaemic damage of brain microvessels: Inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998, 65(1):1-9. 9667553
25. Fagan SC Hess DC Hohnadel EJ Pollock DM Ergul A: Targets for vascular protection after acute ischemic stroke. Stroke 2004, 35(9):2220-2225. 10.1161/01.STR.0000138023.60272.9e 15284446
26. Fagan SC Nagaraja TN Fenstermacher JD Zheng J Johnson M Knight RA: Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res 2003, 25(4):377-382. 10.1179/016164103101201526 12870264
27. Romanic AM White RF Arleth AJ Ohlstein EH Barone F: Matrix metalloproteinase expression increases after cerebral focal ischemia. Stroke 1998, 29:1020-1030. 9596253
28. Rosenberg GA Estrada EY Dencoff JE: Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29(10):2189-2195. 9756602
29. Caldwell RB Bartoli M Behzadian MA El-Remessy AE Al-Shabrawey M Platt DH Liou GI Caldwell RW: Vascular endothelial growth factor and diabetic retinopathy: Role of oxidative stress. Curr Drug Targets 2005, 6(4):511-524. 10.2174/1389450054021981 16026270
30. Silvestre JS Levy BI: Molecular basis of angiopathy in diabetes mellitus. Circ Res 2006, 98(1):4-6. 10.1161/01.RES.0000200396.90220.41 16397150